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Abstract
Chemotherapy induces apoptosis and tumor regression primarily through activation of p53-mediated transcription.
Neuroblastoma is a p53 wild type malignancy at diagnosis and repression of p53 signaling plays an important role in its
pathogenesis. Recently developed small molecule inhibitors of the MDM2-p53 interaction are able to overcome this
repression and potently activate p53 dependent apoptosis in malignancies with intact p53 downstream signaling. We used
the small molecule MDM2 inhibitor, Nutlin-3a, to determine the p53 drug response signature in neuroblastoma cells. In
addition to p53 mediated apoptotic signatures, GSEA and pathway analysis identified a set of p53-repressed genes that
were reciprocally over-expressed in neuroblastoma patients with the worst overall outcome in multiple clinical cohorts.
Multifactorial regression analysis identified a subset of four genes (CHAF1A, RRM2, MCM3, and MCM6) whose expression
together strongly predicted overall and event-free survival (p,0.0001). The expression of these four genes was then
validated by quantitative PCR in a large independent clinical cohort. Our findings further support the concept that
oncogene-driven transcriptional networks opposing p53 activation are essential for the aggressive behavior and poor
response to therapy of high-risk neuroblastoma.
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Introduction
Neuroblastoma (NB), an embryonal tumor arising in tissues of the
sympathetic nervous system, is the most common cancer diagnosed
during the first year of life and accounts for 13% of all deaths due to
childhood malignancies. Despite intense multimodality therapy, at
least half of high-risk patients will experience relapse that is almost
always fatal [1]. Much of the difficulty in devising effective therapies
for this latter group of patients lies in the heterogeneity of their
disease, which can be attributed largely to the interaction of multiple
genetic factors, including both sequence and copy number variants
[2,3]. Amplification of the MYCN gene has emerged as one of the
most reliable indicators of aggressive and treatment-resistant
neuroblastoma, yet 30% to 40% of high-risk tumors lack this
feature [1]. Genomic studies, including massively parallel DNA
sequencing, have failed to reveal additional recurrent molecular
lesions in neuroblastoma, with the exception of ALK mutations
found in a small percentage of high-risk tumors [4,5,6].
A number of previous observations confirm that wild-type p53
alleles are present in the vast majority of cases of newly diagnosed
neuroblastoma, but that p53/MDM2/ARF responses to chemother-
apy are repressed, in part due to unscheduled inhibition of p53 by
MDM2 [7,8,9]. This suggests that down- regulation of the p53 axis
may underlie the treatment resistance typically seen in high-risk
neuroblastoma. To further investigate downstream p53-effector genes
contributing to this cancer phenotype, we used Nutlin-3a, an MDM2
antagonist, which specifically activates p53 leading to apoptosis and
tumor regression of both chemosensitive and chemoresistant
neuroblastoma cell lines [10,11,12]. We compared gene expression
profiles before and after Nutlin treatment and used bioinformatic
approaches to identify p53 drug response genes whose aberrant
expression in high-risk disease may limit p53 activation in response to
genotoxic chemotherapy, increasing the risk of disease progression
and relapse. With this approach we identified four genes that are
highly over expressed in high-risk neuroblastoma (CHAF1A, RRM2,
MCM3, and MCM6) whose expression strongly correlates with poor
outcomes. Importantly, these genes are all directly repressed by
Nutlin-3a-induced p53 activation, are markers of aggressive disease in
other cancers, and have functions related to tumorigenesis and
aberrant DNA replication and transcription [13,14,15,16].
Methods
Tissue Culture
JF (ATCC), IMR32 (ATCC), LAN5 (LS Metelitsa, Houston
TX), and LAN1 (ATCC) human NB lines were maintained in
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RPMI 1640; human colorectal cancer cell line, HCT 116 (ATCC),
and human breast cancer cell line, MCF7 (ATCC), in McCoy’s 5A
and DMEM plus 1% insulin respectively; human osteosarcoma
line, SJSA-1 (ATCC), in RPMI 1640 medium with 10 mM
HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L
sodium bicarbonate; primary neuroblastoma lines (p202, p218,
pH) (Texas Children’s Cancer Center, Houston, TX) and
CHLA255 line (LS Metelitsa) in IMDM with 20% FBS and
0.1% ITS. The p53-mutant NB line, SJ3-12 (21 amino acids
deletion in the DNA binding domain), was provided by Dr. Dirk
Geerts, University of Amsterdam, the Netherlands and used as
control [9]. Nutlin-3a (provided by Dr. Vassilev - Roche, Nutley,
NJ) was used at the concentration of 10 uM (in DMSO).
Oligonucleotide Microarray Data Analysis
Total RNA was isolated using RNAeasy kit (Quiagen) from the
early passage cell line p202 at the 3, 8 and 16 hrs time points.
Using AffymetrixTM U133a microarrays, we compared expression
profiles of Nutlin-3a and Nutlin-3b (inactive enantiomer) treated
p202 primary NB cells over time points. Two biological replicates
Figure 1. MDM2 inhibition stabilizes p53 and induces apoptosis and p53 signaling pathways in neuroblastoma cells. (A) Consistent
with our previously data [11], Western blotting showed an increase in p53 levels within 4 hours exposure to Nutlin-3a in p202, p218, and IMR32 cells,
confirming that the p53 signaling pathway is active in our system. (B) Apoptosis induction was tested in five established neuroblastoma lines (JF,
IMR32), early passage neuroblastoma tumor cultures (p202, p218, H), and four non-neuroblastoma human solid tumors including colorectal (HCT116),
breast (MCF7) and osteosarcoma (SJSA-1). SJSA-1 line differs by the level of MDM2 expression, being amplified 25 fold. A p53 mutant neuroblastoma
line (SJ3-12), which lacks part of the DNA binding domain, was used as control. Proliferating cells were treated with Nutlin-3a for 24 hours and TdT-
positive fraction was measured by flow cytometry. (C) Pathways enriched upon Nutlin-3a treatment: p53 signaling (GSEA ID: M6370), DNA damage
(GSEA ID: M8378), and chemotherapy response (bleo_human_lymph) genes. Vertical columns separate Nutlin-3a versus Nutlin-3b at 3, 8, and
16 hours, horizontal rows indicate genes.
doi:10.1371/journal.pone.0079843.g001
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Figure 2. Correlation of p53 repressed genes and poor prognosis. (A) Heat map of the gene set significantly down-regulated by Nutlin-3a
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were carried out for time-series experiments. Microarray data
were analyzed by an ANOVA time series model using FDR , 0.1
as a statistical cutoff. Class and time comparison analysis identified
probe sets differentially expressed between Nutlin treatments (class
effect) and time points (time effect). Data were clustered using
Cluster 3.0, with centered correlation as distance measure for both
genes and arrays.
Gene Set Enrichment Analysis (GSEA)
For each time point, genes were ranked with respect to the
average expression change upon Nutlin-3a treatment. GSEA was
then performed for each of the three time points using gene
permutation alternative. Enrichment analysis was done with
default parameter settings. An enrichment score was calculated
for each gene set (KS-statistics) reflecting if the genes in the
particular gene set appeared in the top (positive score), in the
bottom (negative score), or were randomly distributed (close to
zero score). These scores were compared with scores calculated
from 1,000 randomly permuted gene lists, in order to calculate
false discovery rates (FDR) (cutoff at FDR=0.05) [17].
Clinical Patient Cohort Groups
1. Oberthuer set (n = 251), discovery set 1. 251 NB tumors
profiled on custom Agilent 44k arrays and downloaded from
ArrayExpress EBI (http://www.ebi.ac.uk/arrayexpress) (E-
TABM-38) [18].
2. Neuroblastoma Research Consortium (NRC) set (n = 101),
discovery set 2. 101 NB tumors profiled on the Human Exon 1.0
ST Affymetrix array [19].
3. Wang set (n = 99), discovery set 3. 99 NB tumors profiled on
Affymetrix U95Av2 array (Gene Expression Omnibus -GEO-
database, http://www.ncbi.nlm.nih.gov/geo/) [20].
4. Versteeg set (n = 88), discovery set 4. 88 NB tumors profiled
on the Affymetrix HGU133plus2.0 platform (R2 database,
microarray analysis and visualization platform, http://r2.amc.nl).
5. Khan set (n= 56), discovery set 5. 56 primary NB tumors
(Oncogenomics, http://home.ccr.cancer.gov/oncology/oncogenomics)
[21].
6. Vermeulen set (n = 348), discovery set 6. 348 NB tumors
taken from the International Society of Pediatric Oncology,
European Neuroblastoma Group (SIOPEN) and from the
Gesellschaft fuer Paediatrische Onkologie und Haematologie
(GPOH). Patients were only included if primary untreated tumor
RNA samples were available and of sufficient quality [22].
Expression of the four gene signature was evaluated in this cohort
using real-time quantitative PCR.
Data Analysis and Statistics of Gene Expression in
Neuroblastoma Tumors
Gene expression data were evaluated according to methods
previously developed for assessment of gene/survival outcomes
[19,22]. Signature scores of the 25- or 4-gene lists were obtained
by calculating the sum of the ranks of the (standardized) expression
values of the 25 or 4 genes across the different samples in a dataset.
Expression of the gene set correlates with signature score [23].
Alternatively, we performed Prediction Analysis for Microarrays
(PAM) classification using the MCR estimate R package. Kaplan-
Meier survival analysis and log-rank analysis were carried out
using the R survival package (R version 10.1). Multivariate logistic
regression analyses were done using SPSS (version 16). Currently
used risk factors such as age at diagnosis ($12 months vs. ,12
months), International Neuroblastoma Staging System (INSS)
stage (stage 4 vs. other stages), and MYCN status (amplified vs. non-
amplified) were tested. GEMS algorithm [24] was used to
construct support vector machine (SVM) predictors using 20-fold
cross-validation for each clinical factor: death event (DE), relapse
event (RE), and INSS stage. The efficiency of the predictor was
estimated by a receiver operator characteristic (ROC) analysis and
recorded as the area under the curve (AUC).
Real-Time qPCR
A qPCR assay was designed for each of the four genes and five
reference genes by PrimerDesign and went through an extensive in
silico validated analysis using BLAST and BiSearch specificity,
amplicon secondary structure, SNP presence, and splice variant
analysis. The mean amplification efficiency was 98%. Primer
design and real time quantitative PCR analysis were performed as
described [22]: primer sequences are available in RTPrimerDB
[25]: CHAF1A (ID= 8273), RRM2 (ID= 8270), MCM6
(ID=8271), MCM3 (ID= 8272) and reference genes: HPRT1
(ID=5), SDHA (ID=7), UBC (ID= 8), and HMBS (ID= 4). Data
handling and calculations (normalization, rescaling, inter-run
calibration, and error propagation) were done in qBasePlus
version 1?1 (http://www.qbaseplus.com) [26][27].
Plasmids and Antibodies
ShRNA mediated p53 knockdown: To knock down p53
expression, second generation lentiviruses expressing shp53 and
shLuc control were used as described [28]. Briefly, 293T cells were
transfected with pLSLPw construct along with packaging
plasmids, pVSVG and pLV-CMV-delta 8.2 by using lipofecta-
mine. Virus-containing supernatants were collected at 48 and
72 hours and neuroblastoma cells transduced in the presence of
8 mg/ml polybrene (Sigma).
Results
Transcriptional profiling of p53 response in
neuroblastoma identifies important genes with respect
to outcome
To initially assess the p53-dependent response we used the
MDM2 inhibitor Nutlin-3a to stabilize p53 in a panel of primary
(p202, p218, and H) and established neuroblastoma lines and
tested its ability to induce apoptosis in neuroblastoma cells
compared to other solid tumors. At 24 hours all neuroblastoma
lines showed a higher percentage of apoptosis compared to non-
neuroblastoma lines. Consistent with our previously published
data [11], Western blot analysis showed a very rapid increase in
p53 levels within four hours exposure to Nutlin-3a, confirming
that the p53 signaling pathway is active in our lines (Figure 1A
and 1B). Interestingly, p53 levels return to baseline at later time
points, likely due to robust MDM2-mediated ubiquitination and
degradation in these cell lines. We then compared the expression
profiles of a MYCN amplified primary neuroblastoma line (p202)
but not Nutlin-3b. (B) Heat map with hierarchical clustering of the gene set with respect to neuroblastoma prognosis (discovery set 5). (C) Kaplan–
Meier and log-rank analysis for progression-free (PFS) and overall (OS) survival of discovery set 2 based on 25 gene set: survival of 101 neuroblastoma
patients in the 4 quartiles of the signature score. Numbers in parentheses refer to number of patients who experienced an event. (D) Multivariate
logistic regression analysis: Odds Ratio and p-values are shown for disease stage (stage 4 vs. other), age (, or . 12 months), MYCN status (amplified
vs. non-amplified), and the 25-gene signature score according to methods previously published [19].
doi:10.1371/journal.pone.0079843.g002
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Figure 3. The four-gene signature predict neuroblastoma outcome. Kaplan–Meier and log-rank analysis for progression-free (PFS) and
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treated with Nutlin-3a or its inactive enantiomer Nutlin-3b for 3,
8, and 16 hours. As expected for a p53 wild-type tumor, we
identified a large number of genes regulated by p53: 1285 genes
differentially expressed between the two Nutlin treatments (class
effect) and 201 genes differentially expressed between time points
(time effect) (Table S1 and Table S2).
We then used Gene Set Enrichment Analysis (GSEA) to analyze
genes and cellular pathways mainly affected by p53 activation. For
each time point genes were ranked with respect to the average
change in expression. Based on these ranked gene lists GSEA was
performed [17]. As expected, three gene sets, p53 signaling (GSEA
ID: M6370), DNA repair (GSEA ID: M8378), and chemotherapy
response (bleo_human_lymph) were highly up-regulated due to
over expression of known p53 target genes (Figure 1C).
By contrast, a fourth gene set was down-regulated upon p53
activation in neuroblastoma cells. This set (GSEA ID: M18562)
included 57 unique genes described to be repressed both by
HIF1A and hypoxia in endothelial cells (p,0.0001) [29] (Figure
2A). p53 has long been shown to play key roles in responding to
DNA damage, hypoxia, and oncogenic activation. Hypoxia is also
known to modulate the p53 transcriptional activity in a manner
dependent and independent of HIF1A, the main transcription
factor activated by hypoxia [30]. As repression of p53 functions is
critical to neuroblastoma tumorigenesis, we hypothesized that
these p53-repressed genes may be important in neuroblastoma
biology and asked whether they could define patient outcome. We
found that high expression of a subset of this gene set (25 genes)
correlated with poor survival in a cohort of 56 neuroblastoma
tumor samples (discovery set 5) [21] (Figure 2B and Table S3).
We next investigated the prognostic value of this subset of 25
genes in an independent set of 101 neuroblastoma samples
(discovery set 2) by calculating signature scores as previously
described [19]. Increased expression of this gene set significantly
correlated with poor outcome by log-rank analysis (overall survival
(OS) p = 0.00018; progression-free survival (PFS) p= 0.00013)
(Figure 2C). In addition, multivariate analysis incorporating
signature score, MYCN status, stage and age demonstrated that
samples with high expression of this gene set had five times higher
predicted and independent mortality than samples with low
expression (odds ratio: 4.826; p = 0.026) (Figure 2D). The
predictive power of this gene set was then independently validated
in three additional clinical cohorts of high-risk patients with
Kaplan-Meier and log-rank analysis (discovery set 1 [18] - 251
patients: OS p,0.00001, PFS p,0.00001), discovery set 3 [20] -
99 patients: OS p,0.05, PFS p,0.005), and discovery set 4 - 88
patients: OS p,0.005 PFS, p,0.01) (Figure S1).
Identification of a four-gene signature with significant
prognostic value in neuroblastoma patients
We predicted that a subset of these 25 genes reflected a
fundamental aspect of the p53-mediated response, and therefore
we sought to define which p53 repressed genes mostly contributed
to the prognostic power of this signature. Thus, a multivariate
logistic regression analysis of 101 patients of the discovery set 2
(with at least 36 months follow up) was performed as described in
the Methods section. This analysis revealed a subset of four genes
(CHAF1A, RRM2, MCM3, and MCM6) as independent predic-
tor of overall survival (p,0.1). The correlation of survival with
signature score based on the expression of these four genes was
then validated in three independent data sets (discovery set 1- 251
patients: OS p,0.00001, PFS p,0.00001, discovery set 3 - 99
patients: OS p,0.005, PFS p,0.005, and discovery set 4 - 88
patients: OS p,0.00001, PFS p,0.0005) (Figure 3A, 3B and
3C).
We also applied an alternative method based on a discovery and
validation strategy to assess the power of the four genes to predict
mortality, relapse, and INSS stage. A classifier able to predict these
clinical factors was independently generated by the SVM (Support
Vector Machine) algorithm (discovery set 4, n= 88 patients) [24].
The classifier was then validated in two independent patient
cohorts (discovery set 1 - 251 patients and discovery set 5 – 56
patients). ROC-curve analysis (AUC) shows that the classifier
containing only the four genes performs better than the classifier
containing all 25 genes in predicting mortality, relapse, and INSS
stage (Figure 3D and 3E).
Independent validation of the four-gene signature by
quantitative-PCR in a large clinical cohort
Extending these findings to an additional large independent
clinical cohort of neuroblastoma patients, we performed qPCR to
evaluate gene expression of CHAF1A, RRM2, MCM3 and
MCM6 in tumor samples from 384 patients enrolled in the
International Society of Paediatric Oncology Europe Neuroblas-
toma Group (SIOPEN) and the Gesellschaft fuer Paediatrische
Onkologie und Haematologie (GPOH) clinical trials (validation set
6) [22]. Both signature score and PAM classification show that the
expression of these four genes as determined by qRT-PCR
distinguishes patients with respect to progression-free (p,0?0001)
and overall survival (p,0?0001) (Figure 4A and 4B). Progres-
sion-free survival at five years from the date of diagnosis was 0.793
(95% CI 0.742 – 0.847) for the group of patients at low molecular
risk compared with 0.487 (95% CI 0.366– 0.649) for the group of
patients at high molecular risk. The five year overall survival was
0.916 (95% CI: 0.878–0.955) and 0.697 (95% CI 0.574 –0.847) in
the low and high molecular risk groups, respectively.
Currently, the strongest predictive risk factors used for
neuroblastoma risk stratification are age, stage, tumor histology,
and MYCN gene amplification status. Multivariate logistic
regression analysis revealed that high expression of the four genes
predicts poor survival independently of these clinical features (odds
ratio: 2.4; p,0.01) (Figure 4D). To validate that the four-gene
signature was independent of the major risk factor, MYCN status,
we analyzed only the MYCN single copy stage 4 tumors. Indeed,
the signature can efficiently predict survival in this group of
patients lacking MYCN gene amplification (log-rank analysis, p,
0.05) (Figure 4C).
The four-gene signature is repressed by p53 in
neuroblastoma cells
To test that the expression of these four genes is indeed
regulated by p53, gene expression of RRM2, CHAF1A, MCM3,
and MCM6 was assessed in multiple p53 wild-type neuroblastoma
lines treated with Nutlin-3a. Real-time PCR demonstrated robust
and rapid repression of each of these genes upon treatment
(p,0.005). However, this effect was totally abrogated in neuro-
blastoma p53 mutant (LAN1) cell line which lacks a DNA binding
overall (OS) survival in discovery set 1 (A), set 3 (B), and set 4 (C) based on the four-gene signature score. (D, E) Comparison of signature performance
between all 25 and the 4 selected genes. Results from discovery and validation study strategy. (D) Gene predictors made in discovery set 4 and
predictions made in discovery set 1. (E) Gene predictors made in validation set 4 and predictions made in discovery set 5. X axis indicates clinical
factors: death event (DE), relapse event (RE), and INSS stage; Y axis indicates Area Under Curve (AUC).
doi:10.1371/journal.pone.0079843.g003
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Figure 4. Independent validation of the four-gene signature in a large cohort of neuroblastoma patients (SIOPEN/GPOH). (A)
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domain. In addition, we used ShRNA-mediated knockdown of
p53 in several cell lines and confirmed up-regulation of all four
target genes (Figure 5A, 5B and 5C). Furthermore, analysis of
two publically available independent ChIP-seq data sets [31,32]
confirms clear p53 binding to p53 response elements in the
promoters of these four genes in response to p53 activation (data
not shown). Taken together, these data suggest that these genes are
direct p53 transcriptional targets.
Discussion
As noted above, p53 is rarely mutated in neuroblastoma,
suggesting that repression of downstream effector genes is critical
for tumorigenesis. p53 is a potent transcription factor that
positively and negatively modulates a large number of genes
involved in apoptosis, metabolism, epigenetics, and cell cycle
regulation [33,34]. We used Nutlin-3a, a direct inhibitor of the
p53 E-3 ligase MDM2, to investigate how the p53 drug response
signature is regulated in high-risk neuroblastoma. Starting from
Kaplan–Meier and log-rank analysis for progression-free (PFS) and overall (OS) survival of the SIOPEN/GPOH cohort (discovery set 6): survival of 348
neuroblastoma patients in the 4 quartiles of the signature score. (B) Validation of the signature based on the four-gene PAM classifier. (C)
Classification of the SIOPEN stage 4 tumors with MYCN single copy based on the four-gene PAM classifier. (D) Multivariate logistic regression analysis:
Odds Ratio and p-values are shown for disease stage (stage 4 vs. other), age (,. 1y), MYCN status, and the four-gene signature score.
doi:10.1371/journal.pone.0079843.g004
Figure 5. The four-gene signature is regulated by p53 activity. Activation of p53 represses the four-gene signature. (A, B) Quantitative PCR
demonstrates marked decrease of mRNA levels of the four genes after Nutlin-3a treatment (10 uM for 8 hours) in multiple p53 wild-type
neuroblastoma lines (shown here LAN5 and IMR32). However, this effect is completely abrogated after p53 silencing or when the effect of Nutlin-3a is
tested in a p53 mutant neuroblastoma cell line (LAN1) (C). Each error bar represents two biological replicates.
doi:10.1371/journal.pone.0079843.g005
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the analysis of a gene set repressed by p53 activity and highly
expressed in high-risk neuroblastoma, we identified a novel four-
gene signature of prognostic relevance. In our retrospective
analysis of three large independent cohorts of neuroblastoma
patients (540 patients total) and 348 patients enrolled in the
SIOPEN/GPOH, this four-gene signature classifies patients with
respect to survival independently of current clinical classification
scheme based on age, stage, MYCN expression and histological
features (INRG Staging System [3]). Notably, our four-gene
signature shows predictive value in neuroblastoma patients with
stage 4 disease and without MYCN amplification. As over 50% of
these patients will relapse and succumb to neuroblastoma despite
current risk stratifications, there is clearly a need for additional
identification of higher risk subgroups that could be given
alternative or additional therapies.
The four genes constituting the signature are involved in DNA
replication and chromatin remodeling. In addition, along with
other genes involved in cell growth, they have been described as
repressed by HIF1A and hypoxia in endothelial cells [29]. It is well
known that tumor microenvironment is intimately connected with
neuroblastoma biology [35,36,37]. While the influence of HIF1A
on the expression of these four genes in neuroblastoma remains to
be defined, we demonstrated that their expression strongly
correlates with poor outcome.
These four genes are likely to have roles in determining
neuroblastoma behavior. RRM2, MCM3 and MCM6 genes have
all been described as cell cycle regulatory genes repressed by p53
in other models as well [13,38]. Ribonucleotide Reductase M2
subunit (RRM2), which is expressed when DNA replication
occurs, is overexpressed in a number of solid tumors and is an
established anti-cancer target [15]. Additional evidence suggests
that Ribonucleotide Reductase (RR) acts as a positive determinant
for tumor cell proliferation and metastasis as well as the
development of chemoresistance [39]. p53 and RRM2 also
directly interact to regulate DNA damage responses [38]. A
recent phase I clinical trial involving the administration of RRM2
siRNA via nanoparticle to patients with solid cancers showed
promising results [40]. In addition, several inhibitors (like triapine
and GTI-2040) have been studied as potential inhibitors of RRM2
activity and have been evaluated in phase I clinical trials [41]. A
recent study suggests that RRM2 contributes to the stabilization of
Bcl-2, a marker of chemoresistance [42]. BCL2 levels are high in
the majority of neuroblastoma tumors. These observations suggest
that suppression of Bcl-2 by targeting RRM2 may be an effective
strategy for restoring chemo-sensitivity in neuroblastoma.
Growing data support the importance of perturbations of the
DNA replication machinery in driving cancer. The minichromo-
some maintenance (MCM) gene family is essential for DNA
replication and is frequently upregulated in various cancers.
Furthermore, increased expression of MCM genes has been shown
to correlate with poorer patient survival rates in other tumor types
[43,44,45]. Notably, all the MCM genes, including MCM7, are
direct transcriptional targets of MYCN and E2F [16,46]. In
addition, deregulation of G1-S checkpoint and E2F target genes
correlates with poor outcome in neuroblastoma [47], further
supporting a potential oncogenic role of MCM genes in
neuroblastoma.
The histone chaperone molecule, CHAF1A (CAF p150), is a
primary component of the chromatin assembly factor 1 (CAF-1)
which is vital for DNA assembly during S-phase [14,48]. CHAF1A
inactivates cell proliferation, regulates DNA repair, and controls
epigenetic marking in embryonic stem cells [49]. CHAF1A is also
a known epigenetic modifier. By participating in a complex with
MBD1 and SETDB1, CHAF1A promotes H3K9 trimethylation
and heterochromatin formation [48,50]. Importantly, CHAF1A
overexpression has been linked to tumor progression, genomic
instability, and cancer susceptibility in other tumor types including
glioma [51,52,53].
The tumor suppressor p53 is very rarely mutated in primary
neuroblastoma at diagnosis and its downstream effectors are
functionally intact [8,54]. However, multiple hits seem to
cooperate to impair p53 functions in neuroblastoma, including
deregulation of the ARF/MDM2 pathway [55], expression of
microRNAs targeting p53 pathways [56], and repression of p53-
mediated autophagy [57]. We demonstrate here that transcrip-
tional profiles of high-risk neuroblastoma show over- expression of
genes that are repressed by p53, and furthermore, a subset of these
genes has strong prognostic value, suggesting they are involved in
overcoming chemotherapy-induced p53 activity. The therapeutic
approach of ‘reactivating p53’ (e.g. by MDM2 antagonists, or
delivery of wild type p53) for neuroblastoma, which develops in
the context of MYCN-mediated p53 repression is an active area of
investigation with several early phase clinical trials underway
[58,59]. Our data further support these approaches and suggest
additional targets for incorporation into future translational
studies.
Supporting Information
Figure S1 Kaplan-Meier and log-rank analysis for
progression free and overall survival of three indepen-
dent cohorts of NB patients stratified according the
expression of the 25 genes. Survival of 251 patients of
discovery set 1 (A), 99 patients of discovery set 3 (B), and 88
patients of discovery set 4 (C) in the 4 quartiles of the signature
score. Represented is the number of patients at low and high-risk
as predicted by the 25-gene signature. Numbers in parentheses
refer to number of patients who experienced an event.
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Table S1 Selected genes modulated by Nutlin-3a treat-
ment. Genes differentially expressed between Nutlin-3a and
Nutlin-3b treatment (class effect – Table S1) and between time
points (time effect – Table S2) are listed.
(XLSX)
Table S2 Selected genes modulated by Nutlin-3a treat-
ment. Genes differentially expressed between Nutlin-3a and
Nutlin-3b treatment (class effect – Table S1) and between time
points (time effect – Table S2) are listed.
(XLSX)
Table S3 Correlation of the 25 genes with survival in
discovery set 5. The list of the 25 genes repressed by p53 and
the correlation of their expression with stage of disease in 56
neuroblastoma patients are shown.
(XLS)
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